AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer ...

AngioDynamics received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in intermediate-risk ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for ...

AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...

Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early ...

AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer patients. The system, which was already FDA-cleared for the surgical ...

Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate ... System in patients with immediate-risk prostate cancer. The results reinforced findings from ...

European Union: The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer. About AngioDynamics, Inc. AngioDynamics is a leading and ...

(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient ...